Clinical Trial Detail

NCT ID NCT04032080
Title Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By Prexasertib (ExIST)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Baylor Research Institute
Indications

triple-receptor negative breast cancer

Therapies

Prexasertib

LY3023414

Age Groups: adult senior

No variant requirements are available.